Psyence Group Inc.
Other OTC•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Mr. Jody Aufrichtig
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 200 Bay Street Toronto ON Canada M5J 2J1
- IPO Date
- May 31, 2022
- Website
- psyence.com
- Similar Companies
- Business
- Psyence Group Inc., a life science biotechnology company, engages in the commercial psilocybin mushroom cultivation and production activities. Its natural psilocybin is used for the treatment of a range of mental health disorders and other medical conditions. The company is developing pharmaceutical preparations of psilocybin doses to help heal psychological trauma and diagnosable disorders, including anxiety, depression, post-traumatic stress disorder, and grief and bereavement. It also focuses on the development, distribution, and sale of over-the-counter non psilocybin containing functional mushroom nutraceutical products under the GOODMIND brand. Psyence Group Inc. was founded in 2019 and is based in Toronto, Canada.
Company News
Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.
Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.
Psyence Biomed Announces Closing of $2.0 Million Private Placement
Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements
Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial
Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial
Psyence Biomed Executes Binding Agreements with Optimi Health Corp.
Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations
Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress
Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation
Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq
Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development
Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical
Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant
Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs
Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs